---
title: "Retatrutide Side Effects Outside Trials: What Users Report"
description: "A JAMA Network Open study of 7,823 people taking unapproved retatrutide: appetite, fatigue, nausea and heart-rate complaints, compared with the trial data."
url: https://retatrutide.med/blog/retatrutide-real-world-side-effects
date: 2026-10-22
lastUpdated: 2026-10-22
author: "retatrutide.med Editorial"
category: "analysis"
tags: ["retatrutide side effects", "real-world", "reta side effects", "heart rate", "dysesthesia", "nausea", "fatigue", "insomnia", "JAMA Network Open", "gray market", "Reddit"]
source: retatrutide.med
sourceType: "blog post"
license: CC-BY-NC-SA-4.0
canonical: https://retatrutide.med/blog/retatrutide-real-world-side-effects
---
**Short answer:** the first large study of people taking retatrutide outside clinical trials, published in *JAMA Network Open* on October 1, 2026, analysed social-media posts from users of unapproved products. Among 7,823 people who described at least one symptom, the most common were **increased appetite (17.1%), fatigue (15.2%), increased energy (12.4%) and nausea (11.6%)**, with about **1 in 20 reporting a faster heart rate**. In the controlled trials, nausea, diarrhea, vomiting and constipation were far more common and appetite went down, not up. The difference is a clue that what people are injecting, and how, is not what was tested. The authors stress the data cannot prove cause or measure how often effects happen.

For the trial side-effect profile in full, see [Retatrutide Side Effects: What Studies Show](/blog/retatrutide-side-effects-what-studies-show) and our [side effects overview](/knowledge-base/side-effects).

## About the study

The researchers analysed **148,640 Reddit posts and comments** from 38,936 users in 27 communities, written between May 2021 and December 2025. A language model identified people describing current use of retatrutide and pulled out the symptoms they mentioned, which were mapped to standard medical terms; a sample was checked by hand.

- **13,589 users** described current use of retatrutide (posts from March 2023 to December 2025).
- **7,823 of them (57.6%)** reported at least one symptom other than weight loss or reduced appetite. Percentages below are of this group.

The products were not approved, the doses were self-chosen, and many users may have combined several peptides.

## What users reported

| Area | Symptom (% of 7,823 users) |
|---|---|
| Appetite and energy | Increased appetite 17.1; fatigue 15.2; increased energy 12.4; food cravings 7.3; hunger 4.7 |
| Digestive | Nausea 11.6; constipation 4.5; diarrhea 4.4; vomiting 2.6 |
| Sleep and mood | Insomnia 6.1; anxiety 3.8 |
| Heart and circulation | Increased heart rate 4.8; racing heart (tachycardia) 3.8; palpitations 1.9; low blood pressure 0.8 |
| Skin sensations | Pain from light touch (allodynia) 2.1; heightened skin sensitivity (hyperesthesia) 2.1; tingling (paresthesia) 1.4; sensitive skin 1.4; dysesthesia 0.7 |
| Other | Muscle growth 4.1; low blood sugar 2.1; muscle loss 2.0; injection-site pain 1.1; hair loss 0.6 |

The authors' own conclusion: "These findings should be considered hypothesis-generating." The analysis "cannot assess incidence, causality, dose-response, or comparative safety."

## How this compares with the clinical trials

In TRIUMPH-1, the largest trial, Lilly reported these rates at the 12 mg dose over 80 weeks, against placebo:

| | Retatrutide 12 mg | Placebo |
|---|---|---|
| Nausea | 42.4% | 14.8% |
| Diarrhea | 32.0% | 13.5% |
| Constipation | 26.1% | 10.9% |
| Vomiting | 25.3% | 4.8% |
| Dysesthesia | 12.5% | 0.9% |
| Stopped because of side effects | 11.3% | 4.9% |

Lilly said these effects were generally mild to moderate and most resolved during treatment. In TRIUMPH-2, in people with type 2 diabetes, low blood pressure occurred in 6% at 12 mg against under 1% on placebo.

Three differences stand out.

**1. Appetite went up for many self-users.** Retatrutide suppresses appetite in trials; that is how it produces weight loss. Increased appetite was the single most common complaint online. Plausible explanations include doses too low or too infrequent, products that had degraded or contained little or no retatrutide, and people describing hunger returning between doses or after stopping. The study cannot tell these apart.

**2. Digestive side effects were reported far less often.** This probably reflects how the data was collected rather than better tolerance. People post about what surprises or worries them, not everything they feel, so a social-media count is not comparable to a trial in which every symptom is asked about and recorded.

**3. Heart rate and sensation complaints appear in both.** These are the two effects that set retatrutide apart in trials (below), and they surface in user reports too.

## Heart rate: what the trials show

Drugs that act on GLP-1 receptors raise resting heart rate a little, and retatrutide's glucagon component may add to that. In the Phase 2 obesity trial (*NEJM*, 2023), "dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter." The trial's supplementary appendix reports that at 24 weeks, 24-hour average heart rate had risen by **9.2 beats per minute** on 12 mg against 0.8 on placebo, from a starting average of 76.

In the user reports, 4.8% described a faster heart rate and 3.8% a racing heart. Two deaths reported to the FDA in 2026 after use of black-market "retatrutide" involved a fast heartbeat and cardiac arrest, although the reports do not prove the product caused them (see [Black-Market Retatrutide: Reported Deaths](/blog/retatrutide-black-market-deaths)). Anyone using an unverified product who notices a persistently fast or irregular heartbeat, chest pain or fainting should seek medical care.

## Dysesthesia and other skin sensations

Dysesthesia, an unpleasant or abnormal sensation such as burning, tingling or skin sensitivity without an obvious cause, was the side effect first flagged as distinctive to retatrutide. In trials it was dose-related and mostly mild, at 12.5% on 12 mg in TRIUMPH-1 and 7% in TRIUMPH-2. Users online described the same family of sensations under several names (allodynia, hyperesthesia, paresthesia), which together add up to more than the 0.7% labelled "dysesthesia." Our article on [dysesthesia](/blog/retatrutide-dysesthesia-what-we-know) covers what is known about it.

## A case report from Switzerland

In October 2026, doctors at University Hospital Zurich reported a woman in her mid-20s hospitalised with five days of nausea, vomiting and loose stools after four weekly, escalating injections of a product reported to contain retatrutide, supplied by a life coach with no medical training. Three standard anti-nausea medicines did not help; she recovered within a week. The authors judged the injections a probable cause.

## The limits of real-world data

- **Unknown product.** Nobody knows what each person injected. Testing of black-market vials has found retatrutide, other drugs, or no peptide at all.
- **Unknown dose.** Users choose their own doses and schedules, often without the four-weekly step-up used in trials.
- **Selective reporting.** People post about some symptoms and not others, so percentages are not rates.
- **No comparison group.** Without placebo, symptoms that are common anyway, such as fatigue and anxiety, cannot be attributed to the drug.
- **Multiple substances.** Many users take several peptides at once.

The study cannot show that retatrutide is more dangerous outside trials, and it cannot show that it is safe. What it does show is that thousands of people are taking an unapproved drug without the monitoring the trials relied on, and reporting effects that deserve clinical attention.

## Frequently asked questions

### What are the most common side effects of retatrutide?

In clinical trials, the most common are nausea, diarrhea, constipation and vomiting, mostly mild to moderate and most frequent while the dose is being increased. Dysesthesia (abnormal skin sensations) and an increase in heart rate are also seen. In reports from people using unapproved products, increased appetite, fatigue, nausea and a faster heart rate were most often mentioned.

### Does retatrutide raise heart rate?

Yes, in trials. In the Phase 2 trial the 24-hour average heart rate rose by about 9 beats per minute at the 12 mg dose at 24 weeks, then declined. About 1 in 20 users in the social-media study reported a faster heart rate.

### Why do some people on "reta" feel hungrier?

The study could not determine why. Possible reasons include a low or degraded dose, a product that is not retatrutide, or hunger returning between doses or after stopping. In trials, retatrutide reduced appetite.

### Are side effects worse with black-market retatrutide?

There is no way to measure that from the available data. What is known is that black-market products have been found to contain the wrong drug, no drug, or bacteria, and that users lack the dosing schedule and monitoring used in trials.

*This article is for education and is not medical advice. Retatrutide is an investigational drug that is not approved by the FDA or any other regulator.*